About 40% to 60% of melanoma has a BRAF protein mutation. The treatments of advanced BRAF mutant melanoma patients are mainly classified into two categories: targeted therapy, such as chemotherapy, which can prevent cancer growth and spreading; and immune therapy, by stimulating the immune system to attack tumor cells.

May 2017 is the Melanoma Awareness Month, which aims to raise awareness of melanoma and increase the chance of early detection for early treatment. Creative Diagnostics provides melanoma antibodies for use with biopharmaceutical, clinical, and life science research applications.